Cirrhotic cardiomyopathy: Getting to the heart of the matter

Hepatology

Volumn 24, Issue 2, 1996, Pages 451-459

  Ma, Zenghua ^a   Lee, Samuel S ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON TETRACHLORIDE; CYCLIC AMP; CYTOKINE; DOBUTAMINE; HUMORAL ANTIBODY; NITRIC OXIDE; OUABAIN;

ADRENERGIC SYSTEM; ALCOHOL CONSUMPTION; CARDIOMYOPATHY; CELL MEMBRANE; CHRONOTROPISM; HEART OUTPUT; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE OVERLOAD; HUMAN; LIPID METABOLISM; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 0029778989     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008690419     Document Type: Article

References (115)

1. Rayes N, Bechstein WO, Keck H, Blumhardt G, Lohmann R, Neuhaus P. Cause of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 1995;120:435-438.
2. Hadengue A, Moreau R, Sogni P, Soupison T, Vilgrain V, Lebrec D. Risk of adverse hemodynamic effects after intrahepatic shunts (TIPS): preliminary results [Abstract]. HEPATOLOGY 1992;62:241A.
3. Pattynama PM, van Hoek B, Kool LJ. Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion. Cardiovasc Intervent Radiol 1995;18:192-195.
4. Franco D, Vons C, Traynor O, de Smadja C. Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 1988;123:987-991.
5. Azoulay D, Castaing D, Eyraud D, Martino W, Bismuth H. Hemodynamic response to transjugular intrahepatic portosystemic shunt in the cirrhotic patient [Abstract]. Gastroenterology 1993;104:873A.
6. Kowalski HJ, Abelmann WH. Cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033.
7. Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989;151: 530-535.
8. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. HEPATOLOGY 1994;20:1356-1358.
9. Murray JG, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958;24:358-367.
10. Lewis FL, Adair O, Rector WG Jr. Arterial vasodilation is not the cause of increased cardiac output in cirrhosis. Gastroenterology 1992;102:1024-1029.
11. Wong F, Liu P, Tobe S, Morali G, Blendis L. Central blood volume in cirrhosis: measurement with radionuclide angiography. HEPATOLOGY 1994;19:312-321.
12. Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969;48:860-868.
13. Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, Bonnevie O, Godtfredsen J. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984;54:852-855.
14. Weissler AM. Current concepts in cardiology: systolic-time intervals. N Engl J Med 1977;296:321-324.
15. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, Gasbarrini G. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. HEPATOLOGY 1991;12:207-216.
16. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IAD, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;26:326-332.
17. Poliner LR, Dehmer GJ, Lewis SE, Parkey RW, Blomqvist CG, Willerson GT. Left ventricular performance in normal subjects: a comparison of the responses to exercise in the upright and supine position. Circulation 1980; 62:528-534.
18. Bernardi M, Trevisani F, Santini C, Zoli G, Baraldini M, Ligabue A, Gasbarrini G. Plasma norepinephrine, week neurotransmitters and renin activity during active tilting in liver cirrhosis: relationship with cardiovascular homeostasis and renal function. HEPATOLOGY 1983;3:56-64.
19. Lee SS, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. HEPATOLOGY 1988;8:647-651.
20. Lunzer MR, Manghani KK, Newman SP, Sherlock SP, Bernard AG, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975;2:382-385.
21. Henriksen JH, Bendtsen F, Sorensen TIA, Stadeager C, Ringlarsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989;97: 1506-1513.
22. Limas CJ, Guiha NH, Lekagui O. Impaired left ventricular function in alcoholic cirrhosis. Circulation 1974;49:755-760.
23. Mikulic E, Munoz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther 1983;34:56-59.
24. Ramond MJ, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol 1986;21:191-196.
25. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial β-adrenergic receptors in cirrhotic rats. HEPATOLOGY 1990;12:481-485.
26. Ingles AC, Hernandez I, Carcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991;260:H1912-H1917.
27. Caramelo C, Fernandes-Munoz D, Santos JC, Blanchart A, Rodriguez- Puyol D, Lopez-Novoa JM, Hernando L. Effect of volume expansion on hemodynamics, capillary permeability, and renal function in conscious, cirrhotic rats. HEPATOLOGY 1986;6:129-134.
28. Ma Z, Miyamoto A, Lee SS. Role of altered β-adrenergic receptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996;110:1191-1198.
29. Spatt SD, Rosenblatt P. The incidence of hypertension in portal cirrhosis: a study of 80 necropsied cases of portal cirrhosis. Ann Intern Med 1949; 31:479-483.
30. Hall EM, Olson AY, Davis FE. Portal cirrhosis: clinical and pathological review of 782 cases from 16,600 necropsies. Am J Pathol 1953;29:993- 1027.
31. Loyke HF. The relationship of cirrhosis of the liver to hypertension: a study of 504 cases of cirrhosis of the liver. Am J Med Sci 1955;230:627- 632.
32. Lunseth JH, Olmstead EG, Forks G, Abboud F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. Arch Intern Med 1958;102:405-413.
33. Preedy VR, Siddiq T, Why H, Richardson PJ. The deleterious effects of alcohol on the heart: involvement of protein turnover. Alcohol Alcohol 1994;29:141-147.
34. Harcombe AA, Ramsay L, Kenna JG, Koskinas J, Why HJ, Richardson PJ, Weissberg PL, Alexander GJ. Circulation antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci 1995;88:263-268.
35. Fleming JW, Wisler PL, Watanabe AM. Signal transduction by G-proteins in cardiac tissue. Circulation 1992;85:420-433.
36. 2-adrenoceptors in the human heart: properties, function, and alteration in chronic heart failure. Pharmacol Rev 1991; 43:203-242.
37. 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J Am Coll Cardiol 1989;14:323-331.
38. 2-Adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol 1987;335:403-411.
39. Strader CD, Fong TM, Graziano MP, Tota M. The family of G-protein- coupled receptors. FASEB J 1995;9:745-754.
40. Schwinn DA, Caron MG, Lefkowitz RJ. The β-adrenergic receptor as a model for molecular structure-function relationships in G-protein - coupled receptors, in Fozzard HA, Harber E, Jennings RB, Katz AM, Morgan HE, eds. The heart and cardiovascular system. Ed 2 New York: Raven, 1992:1657-1684.
41. 2-adrenergic receptor. J Biol Chem 1988;263:15985-15992.
42. Strader CD, Dixon RA, Cheung AH, Candelore MR, Blake AD, Sigal IS. Mutations that uncoupled the β-adrenergic receptor from Gs and increased agonist affinity. J Biol Chem 1987;262:16439-16443.
43. 2-adrenergic receptors. Proc Natl Acad Sci U S A 1988;85:9494-9498.
44. Gilman AG. G-proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987;56:615-649.
45. Hepler JR, Gilman AG. G-protein. Trends Biochem Sci 1992;17:383-389.
46. Iyengar R. Molecular and functional diversity of mammalian Gs-stimulated adenyl cyclase. FASEB J 1993;7:768-775.
47. Neer EJ. Heterotrimeric G Proteins: organizations of transmembrane signals. Cell 1995;80:249-257.
48. Rens-Domiano S, Hamm HE. Structural and functional relationship of heterotrimetric G-proteins. FASEB J 1995;9:1059-1066.
49. Reuter H. Calcium channel modulation by neurotransmitters, enzymes, and drugs. Nature 1983;301:569-574.
50. Solaro RJ, Moir AJ, Perry SV. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 1976; 262:615-617.
51. Moir AJ, Perry SV. Phosphorylation of rabbit cardiac-muscle troponin I by phosphorylase kinase. The effect of adrenaline. Biochem J 1980;191: 547-554.
52. Fujii J, Maruyama K, Tada M, MacLennan DH. Expression and site- specific mutagenesis of phospholamban: studies of residues involved in phosphorylation and pentamer formation. J Biol Chem 1989;264:12950- 12955.
53. Simmerman HK, Collins JH, Theiber JL, Wegener AD, Hones LR. Sequence analysis of phospholamban: identification of phosphorylation sites and two major structure domains. J Biol Chem 1989;261:13333-13341.
54. Yatani A, Brown AM. Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G-protein pathway. Science 1989;245:71-74.
55. Brown AM. Membrane-delimited cell signaling complexes: direct ion channel regulation by G-protein. J Membr Biol 1993;131:93-104.
56. 2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986;1:1409-1410.
57. Brodde OE, Kretsch R, Ikezono K, Zerkowski HR, Reidemeister JC. Human β-receptor: relation of myocardial and lymphocyte β-receptor density. Science 1986;231:1584-1585.
58. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine β-adrenergic receptor function in cirrhotic rats. Am J Physiol 1994;267: G87-G93.
59. 4-induced cirrhosis (CIC) [Abstract]. FASEB J 1994;8: 870A.
60. Braillon A, Gaudin C, Poo JL, Moreau R, Debaene B, Lebrec D. Plasma catecholamine concentrations are a reliable index of sympathetic vascular tone in patients with cirrhosis. HEPATOLOGY 1992;15:58-62.
61. Ring-Larsen H, Hesse B, Henriksen JH, Christensen NJ. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. HEPATOLOGY 1982;2:304-310.
62. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982;307:1552-1557.
63. Gaudin C, Ruget G, Braillon A, Selz F, Cuche JL, Lebrec D. Portal and arterial free and conjugated noradrenaline in two models of portal hypertension in rats. Life Sci 1989;45:1333-1339.
64. Abergel A, Braillon A, Caudin C, Kleber C, Lebrec D. Persistence of a hyperdynamic circulation in cirrhotic rats following removal of the sympathetic nervous system. Gastroenterology 1992;102:656-660.
65. Baue AE, Jones EF, Parking WM. The effects of β-adrenergic receptor stimulation on blood flow, oxidative metabolism, and survival in hemorrhagic shock. Ann Surg 1968;167:403-413.
66. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning of the signal: desensitization of β-adrenergic receptor function. FASEB J 1990;4:2881-2889.
67. Pitcher JA, Inglese J, Jiggins JB, Arriza JL, Casey PJ, Kim C, Benovic JL, et al. Role of βγ subunits of G-protein in targeting the β-adrenergic receptor kinase to membrane-bound receptors. Science 1992;247:1274- 1267.
68. Premont TR, Inglese J, Lefkowitz RJ. Protein kinases that phosphorylate activated G-protein-coupled receptors. FASEB J 1995;9:175-182.
69. Sibley DR, Strasser RH, Caron MG, Lefkowitz RJ. Homologous desensitization of adenylate cyclase is associated with phosphorylation of the β- adrenergic receptor. J Biol Chem 1985;260:3883-3886.
70. Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D. Hemodynamic effects of clonidine-induced decrease in sympathetic tone in patients with cirrhosis. HEPATOLOGY 1987;7:149-154.
71. Lebrec D. β-blockers and portal hypertension, hemodynamic effects, and prevention of recurrent gastrointestinal bleeding. Hepato-gastroenterology 1990;37:556-560.
72. Avegerinos A, Rekoumis G, Klonis C, Papadimitriou N, Gouma P, Pournaras S, Raptis S. Propranol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy: a randomized controlled trial. J HEPATOL 1993;19:301-311.
73. Battarbee HD, Zavecz JH, Roerig SC, O'Donnell JM. Portal vein stenosis and cardiac impairment [Abstract]. Gastroenterology 1993;104:875A.
74. Cahill PA, Wu Y, Sitzmann JV. Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits. J Clin Invest 1994;93:2691-2700.
75. Kakimoto H, Imai Y, Kawata S, Inada M, Ito T, Matsuzawa Y. Altered lipid composition and differential changes in activities of membrane- bound enzymes of erythrocytes in hepatic cirrhosis. Metabolism 1995;44: 825-832.
76. Buters JT, Zysset T, Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem Pharmacol 1993; 46:983-991.
77. Reichen J, Buters JT, Sojcic Z, Roos FJ. Abnormal lipid composition of microsomes from cirrhotic rat liver - does it contribute to decreased microsomal function? Experientia 1992;48:482-486.
78. +-dependent D- glucose transport and altered lipid composition in renal cortical brush- border membrane vesicles from bile duct-ligated rats. J Lip Res 1992;33: 473-483.
79. Tahara D, Nakanishi T, Akazawa S, Yamaguchi Y, Yamaoto H, Akashi M, Chikuba N, et al. Lecithin-cholesterol acyltransferase and lipid transfer protein activities in liver disease. Metabolism 1993;42:19-23.
80. Simon JB. Red cell lipids in liver disease: relationship to serum and to lecithin-cholesterol acyltransferase. J Lab Clin Med 1971;77:891-900.
81. 2-adrenergic receptor: mutation of CYS in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J Biol Chem 1989;264:7564-7569.
82. Casey PJ. Lipid modification of G-proteins. Curr Opin Cell Biol 1994;6: 219-225.
83. Wedegaertner PB, Wilson PT, Bourne HR. Lipid modifications of trimeric G-proteins. J Biol Chem 1995;270:503-506.
84. Miyamoto A, Araiso T, Koyama T, Ohshika H. Adrenoceptor coupling mechanisms which regulate salivary secretion during aging. Life Sci 1993;53:1873-1878.
85. Mukaino S. Clinical observations on electrocardiographic changes in diseases of the liver. Jpn Circ J 1964;28:148-152.
86. Kempler P, Szalay F, Varadi A, Keresztes K, Kadar E, Tanczos E, Petrik J. Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases. Zeitschr Gastroenterol 1993;31(suppl 2):96-98.
87. Calandra S, Raimondo MF, Trevisani F, Sica G, Schepis F, Colantoni A, Raimondo G, et al. Prolonged Q-T interval in cirrhosis: relationship with etiology and severity of liver disease [Abstract]. HEPATOLOGY 1995;22: 67A.
88. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995;22:370-376.
89. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailamil S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-1023.
90. Bastiaanse EM, Jongsma HJ, van der Laarse A, Takens-Kwak BR. Heptanol-induced decrease in cardiac gap junctional conductance is mediated by a decrease in the fluidity of membranous cholesterol-rich domains. J Membr Biol 1993;136:135-145.
91. 1-Adrenoceptors in myocardium: function aspects and transmembrane signaling mechanisms. Physiol Rev 1993;73:469-487.
92. 1-adrenergic receptors. Cardiovasc Res 1993;27:1735-1742.
93. Jaue DN, Ma Z, Lee SS. Cardiac contractility and muscarinic receptor function in cirrhotic cardiomyopathy [Abstract]. HEPATOLOGY 1995;22: 167A.
94. Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. Gastroenterology 1993;104:1722-1726.
95. Fukui H, Matsumoto M, Bode C, Bode JC, Tsujita S, Tsujii T. Endotoxaemia in patients with live cirrhosis and upper gastrointestinal bleeding: detection by the chromogenic assay with plasma Tween 80 pretreatment. J Gastroenterol Hepatol 1993;8:577-581.
96. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, et al. Endotoxemia in patients with chronic liver diseases, presence of relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995;22:165-172.
97. Napoli J, Bishiop GA, McCaughan GW. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology 1994;107:789-798.
98. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-274.
99. de Mikulic LE, Auclair MC, Vernimmen C, Lebrec D, Mikulic E. Plasma from cirrhotic patients induces inotropic changes on cultured rat heart cells. Life Sci 1987;41:2177-2184.
100. Sosa G, Milstein JM, Bennet SH. Escherichia coli endotoxin depresses left ventricular contractility in neonatal lambs. Pediatr Res 1994;35:62- 67.
101. Tanaka N, Kita T, Kasai K, Nagano T. The immunocytochemical localization of tumor necrosis factor and leukotriene in the rat heart and lung during endotoxin shock. Virchows Arch 1994;424:273-277.
102. Kleber G, Braillon A, Gaudin C, Champigneulle B, Cailmail S, Lebrec C. Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats. Gastroenterology 1992;103:282-288.
103. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α. Br J Pharmacol 1995;114:27-34.
104. Ungureanu-Longrois D, Dalligand JL, Kelly RA, Smith TW. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol 1995;27:155-167.
105. Clain JE, Malagelada J, Chadwick VS, Hoffmann. Binding properties in vitro of antacid for conjugated bile acids. Gastroenterology 1977;73:556-559.
106. LaRusso NF, Hoffman NE, Hoffmann AL, Kormann MG. Validity and sensitivity of an intravenous bile acid tolerance test in patients with liver disease. N Engl J Med 1975;292:1209-1214.
107. Jacob G, Nassar N, Hayam G, Ben-Haim S, Edoute Y, Better OS, Bomzon A. Cardiac function and responsiveness to β-adrenoceptor agonists in rats with obstructive jaundice. Am J Physiol 1993;265:G314-G320.
108. Lumlertgol D, Boonyaprapa S, Bunnacheck D, Thanachaikun N, Praisontarangkul OA, Phornphutkul K, Keoplung M. The jaundiced heart: evidence for blunted response to positive inotropic stimulation. Ren Fail 1991;13:15-22.
109. Binah OS, Bomzon A, Blendis LM, Mordechowitz D, Better OS. Obstructive jaundice blunts myocardial contractile response to isoprenaline in the dog: a clue to susceptibility of jaundiced patients to shock. Clin Sci 1985;69:647-653.
110. Pak JM, Adeagbo ASO, Triggle CR, Shaffer EA, Lee SS. Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle. Br J Pharmacol 1994;112:1209-1215.
111. ++-ATPase in cardiac hypertrophy by angiotensin converting enzyme? Basic Res Cardiol 1992;87: 197-204.
112. Battarbee HD, Zavecz JH. Cardiac performance in portal vein-stenosed rats. Am J Physiol 1992;263:G181-G185.
113. Zavecz JH, Battarbee HD, O'Donnell JM. Cardiac β-adrenoceptor-effect or coupling in portal vein-stenosed rats. Am J Physiol 1995;268:G410-G415.
114. Ma Z, Meddings JB, Lee SS. Cardiac plasma membrane physical properties and β-adrenergic receptor function are unaltered in portal-hypertensive rats. HEPATOLOGY 1995;22:188-193.
115. Neruda P; Kalant OJ, trans. Odas Elementales. Farrar, Straus and Giroux, Inc.